Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WD-01
- Development stage
- Phase 1
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
WD-01 is an autologous CAR-T cell therapy under investigation for the treatment of metastatic colorectal cancer. This therapy involves genetically modifying a patient's own T cells with a second-generation Chimeric Antigen Receptor (CAR) that specifically targets Guanylyl Cyclase C (GCC) expressed on cancer cells. The therapy aims to assess the safety and efficacy, including objective response rate and progression-free survival, in patients with metastatic colorectal cancer.
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on WD-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WD-01.